Swing Therapeutics

Swing Therapeutics, founded in 2019, is creating the next generation of safe and effective digital therapeutics for patients with chronic diseases, focusing on addressing autoimmune conditions and chronic overlapping pain conditions (COPCs) such as fibromyalgia, where central pain sensitization plays a significant role. The company is investing in research to support the development and validation of its prescription-based digital therapies. Our team, comprised of passionate scientists, clinicians, and technologists, is collaborating with some of the world’s leading researchers to develop evidence-based, transformative digital treatments. Swing Therapeutics’ near-term goal is to validate its digital program for fibromyalgia treatment and bring it to market as an FDA-approved, prescription-based digital therapeutic.